UTICA, N.Y., April 24 /PRNewswire-FirstCall/ --
CONMED Corporation (Nasdaq: CNMD) announced today record results for the first
quarter ended March 31, 2003.
Sales increased to $118.0 million ($115.5 million at constant exchange
rates) compared to $113.2 million in first quarter of 2002. Reported net
income for the quarter grew to $14.6 million, or $0.50 per diluted share, from
$9.1 million, or $0.35 per diluted share, in last year's comparable quarter.
As previously disclosed, reported net income for the first quarter includes a
one-time net after-tax gain of $4.6 million, or $0.15 per diluted share, from
the previously announced receipt of a settlement of a lawsuit as well as
acquisition and financing related charges (please see below for full
explanation). Excluding these other items, net income for the first quarter
of 2003 was $10.0 million, or $0.35 per diluted share.
The Company's Arthroscopy sales improved to $41.7 million from
$41.3 million in last year's first quarter. Bionx Implants, Inc., which was
acquired by CONMED on March 10, 2003, contributed sales of $0.8 million to the
arthroscopy line's revenues. Within arthroscopy, the Company's line of video
systems improved 6%, while sales of procedure specific and fluid management
products were slightly less than the first quarter of 2002. Powered Surgical
Instrument sales grew 9% to $31.0 million compared to $28.4 million in the
first quarter of 2002 on the strength of the PowerPro(R) group of products.
Electrosurgery and Patient Care revenues were stable with $16.8 million and
$17.3 million, respectively, in the first quarters of 2003 and 2002.
Endoscopy revenues grew 14% to $10.7 million compared to $9.4 million in the
same quarter a year ago. The increase in endoscopy revenues is attributable
to the Core Dynamics acquisition completed on December 31, 2002. The
Integrated Systems product line, which CONMED obtained as a result of the
recent ValMed and Nortrex acquisitions, contributed $0.5 million of revenues
in the first quarter of 2003.
Mr. Joseph J. Corasanti, President and Chief Operating Officer, said, "I
am pleased that we achieved record sales of $118.0 million in our first
quarter of 2003 although this was at the lower end of our expectations. Our
cost management measures and favorable foreign currency translation enabled us
to achieve our targeted operating income, and our litigation settlement
permitted us to pay-down additional debt."
Mr. Corasanti continued, "We reported strong growth in powered instrument
sales due to the momentum we have built in our PowerPro(R) line of battery
powered surgical instruments. In addition, we recently announced that we will
be expanding and reorganizing our orthopedic sales force to maximize coverage
within our markets. Over the next year, we plan to add 50 sales professionals
who will be responsible for selling our orthopedic products for arthroscopy
and powered surgical instruments. These additional 'feet on the street'
should bode well for our sales growth going forward. We continue to hear
positive feedback from the medical community regarding our new Integrated
Systems product line and are excited about the long-term growth opportunities
it provides for CONMED."
Mr. Corasanti added, "We believe that these initiatives together with the
overall strength of our product franchise will enable us to generate sales of
approximately $117 million to $122 million and diluted earnings per share of
approximately $0.34 to $0.37 for the second quarter. To that end, we remain
comfortable with our full-year forecast for top-line growth of 10% over 2002
levels and diluted earnings per share of $1.47 to $1.51. Both of these
forecasted diluted earnings per share amounts exclude the benefit of the
litigation settlement and the charges for acquisition and financing items."
Explanation of Lawsuit Settlement, Acquisition and Financing-Related
Charges
As previously announced, in March 2003, the Company settled a dispute
related to the 1997 acquisition of its orthopedic subsidiary, Linvatec
Corporation, for $9.5 million. Accordingly, the Company recorded the
settlement, less estimated legal expenses of $0.5 million, as a pre-tax gain
of $9.0 million in the first quarter of 2003. Offsetting this gain were
pre-tax charges totaling $1.7 million associated with the integration of the
Company's previously announced Bionx, Core and ValMed acquisitions. In
addition, the Company incurred a $0.2 million pre-tax expense related to the
purchase on the open market of $2.6 million of the Company's 9% subordinated
bonds.
Reconciliation of Forecasted Earnings Per Share
The second quarter 2003 forecasted diluted earnings per share range
excludes a $.01 per share impact of an expected $0.4 million after-tax charge
for the premium to be paid for the anticipated early extinguishment of
$15 million of the Company's senior subordinated debt. It also excludes any
potential acquisition related charges for the Bionx, Core, ValMed and Nortrex
acquisitions which, if they occur, are not presently quantifiable.
The diluted earnings per share forecasted range for the year 2003 excludes
the $.15 earnings per share net benefit of the lawsuit settlement, acquisition
and financing-related charges recorded in the first quarter of 2003, as
described above. It also excludes the earnings per share impact of the
anticipated second quarter 2003 financing and acquisition related charges
described above. Further, it excludes the earnings per share effect of any
potential acquisition related charges which may occur in the third and fourth
quarters of 2003 related to the Bionx, Core, ValMed and Nortrex acquisitions
which, if they occur, are not presently quantifiable.
CONMED Profile
CONMED is a medical technology company specializing in instruments,
implants, and video equipment for arthroscopic sports medicine, and powered
surgical instruments, such as drills and saws, for orthopedic, ENT,
neuro-surgery, and other surgical specialties. The Company is also a leading
developer, manufacturer and supplier of RF electrosurgery systems used
routinely to cut and cauterize tissue in nearly all types of surgical
procedures worldwide, endoscopy products such as trocars, clip appliers,
scissors, and surgical staplers. The Company offers integrated operating room
design and intensive care unit service managers. The Company also
manufactures and sells a full line of ECG electrodes for heart monitoring and
other patient care products. Headquartered in Utica, New York, the Company's
2,500 employees distribute its products worldwide from eleven manufacturing
locations.
Forward-Looking Information
This press release contains forward-looking statements based on certain
assumptions and contingencies that involve risks and uncertainties. The
forward-looking statements are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995 and relate to the
Company's performance on a going-forward basis. The forward-looking
statements in this press release involve risks and uncertainties which could
cause actual results, performance or trends, including the above mentioned
anticipated revenues and earnings, to differ materially from those expressed
in the forward-looking statements herein or in previous disclosures. The
Company believes that all forward-looking statements made by it have a
reasonable basis, but there can be no assurance that management's
expectations, beliefs or projections as expressed in the forward-looking
statements will actually occur or prove to be correct. In addition to general
industry and economic conditions, factors that could cause actual results to
differ materially from those discussed in the forward-looking statements in
this press release include, but are not limited to: (i) the failure of any one
or more of the assumptions stated above, to prove to be correct; (ii) the
risks relating to forward-looking statements discussed in the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 2002; (iii)
cyclical purchasing patterns from customers, end-users and dealers; (iv)
timely release of new products, and acceptance of such new products by the
market; (v) the introduction of new products by competitors and other
competitive responses; (vi) the possibility that any new acquisition or other
transaction may require the Company to reconsider its financial assumptions
and goals/targets; and/or (vii) the Company's ability to devise and execute
strategies to respond to market conditions.
CONMED CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
Three Months Ended March 31, 2002 and 2003
(In thousands except per share amounts)
(unaudited)
2002 2003
Net sales $113,205 $118,034
Cost of sales 54,104 55,966
Cost of sales, nonrecurring - Note A -- 412
Gross profit 59,101 61,656
Selling and administrative expense 34,468 37,145
Research and development expense 3,824 3,703
Other nonrecurring, net - Note B -- (7,492)
38,292 33,356
Income from operations 20,809 28,300
Interest expense 6,628 5,538
Income before income taxes 14,181 22,762
Provision for income taxes 5,105 8,194
Net income $9,076 $14,568
Per share data:
Net income
Basic $.36 $.50
Diluted .35 .50
Weighted average common shares
Basic 25,397 28,876
Diluted 25,969 29,037
Note A - Included in cost of sales in the three months ended March 31,
2002 are approximately $.4 million in acquisition-related costs.
Note B - Included in other items in the three months ended March 31, 2003
are the following: a $9.0 million gain on the settlement of a
contractual dispute; $.2 million in losses on the early extinguishment of
debt; and $1.3 million in acquisition-related costs.
CONMED CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS
(in thousands)
ASSETS
(unaudited)
December 31, March 31,
2002 2003
Current assets:
Cash and cash equivalents $5,626 $6,250
Accounts receivable, net 58,093 60,257
Inventories 120,443 125,721
Other current assets 9,504 9,966
Total current assets 193,666 202,194
Property, plant and equipment, net 95,608 96,326
Goodwill and other assets, net 452,866 494,716
Total assets $742,140 $793,236
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt $2,631 $2,387
Accrued interest 3,794 1,058
Other current liabilities 51,549 54,627
Total current liabilities 57,974 58,072
Long-term debt 254,756 282,949
Other long-term liabilities 42,471 47,219
Total liabilities 355,201 388,240
Shareholders' equity:
Capital accounts 231,701 233,484
Retained earnings 162,391 176,959
Accumulated other comprehensive loss (7,153) (5,447)
Total equity 386,939 404,996
Total liabilities and
shareholders' equity $742,140 $793,236
OTHER FINANCIAL INFORMATION
(unaudited, in thousands)
Three months ended
March 31,
2002 2003
Depreciation 2,206 2,374
Amortization 2,780 2,946
Capital expenditures 3,208 1,710
CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO NET INCOME
BEFORE NONRECURRING ITEMS
Three Months Ended March 31, 2002 and 2003
(In thousands except per share amounts)
(unaudited)
2002 2003
Reported net income $9,076 $14,568
Acquisition-related costs included
in cost of sales -- 412
Other nonrecurring items, net -- (7,492)
Nonrecurring income before income taxes -- (7,080)
Provision for income taxes on nonrecurring income -- 2,549
Net income before nonrecurring items. $9,076 $ 10,037
Per share data:
Reported net income
Basic $0.36 $0.50
Diluted 0.35 0.50
Net income before nonrecurring items
Basic $0.36 $0.35
Diluted 0.35 0.35
Management has provided the above reconciliation of net income before
nonrecurring items as an additional measure that investors can use to compare
operating performance between reporting periods. Management believes this
reconciliation provides a useful presentation of operating performance.
SOURCE CONMED Corporation
 back to top
Related links:
http://www.conmed.com
Company News On-Call:
http://www.prnewswire.com/comp/201850.html
CONTACT:
Robert Shallish, Chief Financial Officer of
CONMED Corporation, +1-315-624-3206; or Investors: Lauren Levine,
Lanie Fladell, or Media: Sean Leous, all of Morgen-Walke
Associates, +1-212-850-5600, for CONMED
|
